News

PipelineReview.com9h
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK, NY, USA I May 30, 2025 I Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase ...
Mirage News11h
Pfizer Combo Halves Death Risk in BRAF V600E Cancer
Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...